Investor's Business Daily on MSN
How Apogee, up almost 20%, plans to take on rival Regeneron's eczema drug
Apogee Therapeutics reported a "best case scenario" Monday for its potential rival to eczema drug, Dupixent.
Considerable on MSN
Apogee signals best-case outlook for Dupixent rival
Apogee Therapeutics signaled a “best case scenario” on Monday for its experimental eczema treatment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results